Voriconazole as Prophylactic Therapy in Lung Transplant Recipients

Stopped early · Phase 4

Conditions studied: Infection

In brief

The purpose of this study is to compare the safety and efficacy of Voriconazole with Itraconazole following lung transplantation.

Key facts

Study ID

NCT00455364

Run by

University of Chicago

People needed

20

Starts

2007-04-01

Expected to finish

2007-04-01

Last updated by the study team

2013-02-06

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Bilateral-lung or single-lung transplant recipients between the ages of 18- 65 years old.
• Patients must be able to give informed consent prior to and again after transplantation

You may not qualify if…

• Lung transplant patients unable to give informed consent.
• Prior adverse reaction to the drug itraconazole or voriconazole

Where it is running

• The University of Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.